S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NASDAQ:RIGL

Rigel Pharmaceuticals Stock Forecast, Price & News

$3.78
+0.01 (+0.27 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.71
Now: $3.78
$3.83
50-Day Range
$3.01
MA: $3.48
$3.81
52-Week Range
$1.23
Now: $3.78
$5.24
Volume1.78 million shs
Average Volume2.49 million shs
Market Capitalization$638.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

348th out of 1,928 stocks

Pharmaceutical Preparations Industry

184th out of 774 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100
Employees163

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share

Profitability

Net Income$-66,890,000.00

Miscellaneous

Market Cap$638.75 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$3.78
+0.01 (+0.27 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

How has Rigel Pharmaceuticals' stock been impacted by Coronavirus?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RIGL shares have increased by 108.8% and is now trading at $3.78.
View which stocks have been most impacted by COVID-19
.

Is Rigel Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Rigel Pharmaceuticals?

Wall Street analysts have given Rigel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rigel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Rigel Pharmaceuticals' CEO?

1,428 employees have rated Rigel Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Rigel Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Rigel Pharmaceuticals
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.04. The biotechnology company earned $18.39 million during the quarter, compared to the consensus estimate of $17.60 million. Rigel Pharmaceuticals had a negative net margin of 26.25% and a negative return on equity of 44.96%.
View Rigel Pharmaceuticals' earnings history
.

What guidance has Rigel Pharmaceuticals issued on next quarter's earnings?

Rigel Pharmaceuticals updated its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.4-18.4 million, compared to the consensus revenue estimate of $17.81 million.

What price target have analysts set for RIGL?

4 Wall Street analysts have issued 12 month target prices for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $7.33 in the next year. This suggests a possible upside of 94.0% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres & CEO (Age 60, Pay $1.01M)
  • Mr. Dean L. Schorno CPA, Exec. VP & CFO (Age 58, Pay $612.53k)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 56, Pay $761.28k)
  • Dr. Esteban S. Masuda, Exec. VP of Research (Age 59, Pay $537.21k)
  • Dr. Wolfgang Dummer M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 55, Pay $170.22k)
  • Mr. Joseph Lasaga, Sr. VP of Corp. Devel. (Age 46)
  • Ms. Lily Cheung, VP of HR
  • Mr. David A. Santos, Exec. VP & Chief Commercial Officer
  • Mr. Tarek Sallam, VP of Marketing

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include DNB Asset Management AS (0.08%), Diversified Trust Co (0.02%) and Pacer Advisors Inc. (0.01%).
View institutional ownership trends for Rigel Pharmaceuticals
.

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Diversified Trust Co, and DNB Asset Management AS.
View insider buying and selling activity for Rigel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Rigel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.78.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $638.75 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 163 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.